Basic and clinical research of treatment for ocular disease by KANPO-drugs

汉方药治疗眼病的基础与临床研究

• 批准号: 08672011
• 负责人: HAYASAKA Seiji
• 金额: $ 0.45万
• 依托单位: TOYAMA MEDICAL AND PHARMACEUTICAL UNIVERSITY
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1996
• 资助国家: 日本
• 起止时间: 1996 至 1997
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-08672011/
• 关键词: KANPO-DRUG; KAKKON-TO; SAIREI-TO; PROSTAGLANDIN E_2; ENDOTOXIN (LIPOPOLYSACCHARIDE); INTRAOCULAR INFLAMATION; UVEITIS; AQUEOUS FLARE; 黄連解毒湯(オーレンゲドクトウ); リポポリサッカライド(LPS); 眼炎症

1. Basic researchWe investigated the effects of KANPO-druds for experimental uveitis. we report the results of new evidence acquired from the experiments.(1) The effects of KANPO-druds for experimental uveitis induced by topical prostaglandin E_2 KANPO-druds of ten-fold doses of human clinical dose were adiministered for 1 week before prostaglandin E_2 (10mug/ml) -treatment.The KANPO-druds of SAIREI-TO,KAKKON-TO and ORENGEDOKU-TO,respectively, did not inhibited the experimental uveitis.(2) The effects of KANPO-druds for experimental uveitis induced by lipopolysaccaharide(1) KAKKON-TO of five-fold doses of human clinical dose were administered for 1 week before lipopolysaccharide (0.5mug/kg) -treatment. But, the experimental uveitis were not inhibited.(2) SAIREI-TO were administered for 1 week before lipopolysaccharide (0.5mug/kg) -treatment. In ten-fold and three-fold doses of human clinical dose of SAIREI-TO,the experimental uveitis were significantly inhibited compared with control.

1。基础研究我们研究了kanpo-druds对实验性葡萄膜炎的影响。我们报告了从实验中获取的新证据的结果。（1）在局部前列腺素e_2 kanpo-druds诱导的kanpo-druds对十倍人类临床剂量的实验葡萄膜炎的影响1周，在前列腺素e_2（10mug/ml）-ML.ML.-the Kanpthe-the Kanpthe-the Kanpthe-the Kanpthe kanpthe-the kanpthe kanplandimister。 Sairei-to，Kakkon-to和Orengedoku-to分别没有抑制实验性葡萄膜炎。（2）kanpo-druds对脂po症诱导的脂肪性葡萄膜炎的影响（1）kakkon-to kakkon-to Kakkon-kakkon-kakkon-kakkon-kakkon-kakkon-kakkon-kakkon-kakkon-kakkon to to to popopoly for五倍的人类临床剂量在1周之前施用了lipopol popolys/lipopheard/kgg。但是，没有抑制实验性葡萄膜炎。（2）在脂多糖（0.5mug/kg）治疗之前，塞雷伊至塞雷河炎。与对照相比，在Sairei-to的十倍和三剂人类临床剂量中，实验性葡萄膜炎受到了显着抑制。